Anna Minarini

List of Publications by Citations

93 papers	3,700 citations	29 h-index	58 g-index
99 ext. papers	4,060 ext. citations	5.7 avg, IF	4.8 L-index

#	Paper	IF	Citations
93	Multi-target-directed ligands to combat neurodegenerative diseases. *Journal of Medicinal Chemistry*, **2008**, 51, 347-72	8.3	816
92	Rational approach to discover multipotent anti-Alzheimer drugs. *Journal of Medicinal Chemistry*, **2005**, 48, 360-3	8.3	206
91	Tacrine derivatives and Alzheimer's disease. *Current Medicinal Chemistry*, **2010**, 17, 1825-38	4.3	180
90	Inhibition of acetylcholinesterase, beta-amyloid aggregation, and NMDA receptors in Alzheimer's disease: a promising direction for the multi-target-directed ligands gold rush. *Journal of Medicinal Chemistry*, **2008**, 51, 4381-4	8.3	170
89	Oxidative stress in Alzheimer's disease: are we connecting the dots?. *Journal of Medicinal Chemistry*, **2014**, 57, 2821-31	8.3	150
88	Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease. *Journal of Medicinal Chemistry*, **2007**, 50, 4882-97	8.3	113
87	Design, synthesis, and biological evaluation of conformationally restricted rivastigmine analogues. *Journal of Medicinal Chemistry*, **2004**, 47, 5945-52	8.3	108
86	Alzheimer's disease: new approaches to drug discovery. *Current Opinion in Chemical Biology*, **2009**, 13, 303-8	9.7	100
85	Multifunctional tacrine derivatives in Alzheimer's disease. *Current Topics in Medicinal Chemistry*, **2013**, 13, 1771-86	3	71
84	Multi-target design strategies in the context of Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces. *Neurochemical Research*, **2014**, 39, 1914-23	4.6	67
83	MTDL design strategy in the context of Alzheimer's disease: from lipocrine to memoquin and beyond. *Current Pharmaceutical Design*, **2009**, 15, 601-13	3.3	64
82	Multitargeted drugs discovery: balancing anti-amyloid and anticholinesterase capacity in a single chemical entity. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2655-8	2.9	55
81	Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer. *Journal of Medicinal Chemistry*, **2008**, 51, 7308-12	8.3	52
80	Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeutics. *Future Medicinal Chemistry*, **2016**, 8, 697-711	4.1	52
79	Design, synthesis, and biological evaluation of substituted naphthalene imides and diimides as anticancer agent. *Journal of Medicinal Chemistry*, **2009**, 52, 7873-7	8.3	48
78	From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease. *Mini-Reviews in Medicinal Chemistry*, **2008**, 8, 960-7	3.2	48
77	Polyamines in drug discovery: from the universal template approach to the multitarget-directed ligand design strategy. *Journal of Medicinal Chemistry*, **2010**, 53, 5906-14	8.3	44

76	Binding profile of the selective muscarinic receptor antagonist tripitramine. *European Journal of Pharmacology*, **1994**, 268, 459-62		44
75	Prazosin-related compounds. Effect of transforming the piperazinylquinazoline moiety into an aminomethyltetrahydroacridine system on the affinity for alpha1-adrenoreceptors. *Journal of Medicinal Chemistry*, **2003**, 46, 4895-903	8.3	41
74	Synthesis and biological activity of some methoctramine-related tetraamines bearing a 11-acetyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]-benzodiazepin-6-one moiety as antimuscarinics: a second generation of highly selective M2 muscarinic receptor antagonists. *Journal of Medicinal Chemistry*, **1993**, 36, 3734-7	8.3	41
73	Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma. *Journal of Controlled Release*, **2015**, 211, 44-52	11.7	40
72	Recent advances in alpha1-adrenoreceptor antagonists as pharmacological tools and therapeutic agents. *Current Topics in Medicinal Chemistry*, **2007**, 7, 147-62	3	40
71	Structure-activity relationships of novel substituted naphthalene diimides as anticancer agents. *European Journal of Medicinal Chemistry*, **2012**, 57, 417-28	6.8	39
70	Design, synthesis, and biological evaluation of symmetrically and unsymmetrically substituted methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. *Journal of Medicinal Chemistry*, **1999**, 42, 5212-23	8.3	37
69	Polyamine conjugation of curcumin analogues toward the discovery of mitochondria-directed neuroprotective agents. *Journal of Medicinal Chemistry*, **2010**, 53, 7264-8	8.3	32
68	Lipoic acid, a lead structure for multi-target-directed drugs for neurodegeneration. *Mini-Reviews in Medicinal Chemistry*, **2006**, 6, 1269-74	3.2	32
67	Universal template approach to drug design: polyamines as selective muscarinic receptor antagonists. *Journal of Medicinal Chemistry*, **1998**, 41, 4150-60	8.3	32
66	Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine. *Journal of Medicinal Chemistry*, **2003**, 46, 954-66	8.3	31
65	An optimized polyamine moiety boosts the potency of human type II topoisomerase poisons as quantified by comparative analysis centered on the clinical candidate F14512. *Chemical Communications*, **2015**, 51, 14310-3	5.8	30
64	Multitarget-directed ligands: innovative chemical probes and therapeutic tools against Alzheimer's disease. *Current Topics in Medicinal Chemistry*, **2011**, 11, 2797-806	3	29
63	Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 3. Effect of replacing the inner polymethylene chain with cyclic moieties. *Journal of Medicinal Chemistry*, **2004**, 47, 6490-8	8.3	29
62	In vitro characterization of tripitramine, a polymethylene tetraamine displaying high selectivity and affinity for muscarinic M2 receptors. *British Journal of Pharmacology*, **1995**, 114, 1507-17	8.6	29
61	Macrocyclic naphthalene diimides as G-quadruplex binders. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 3819-30	3.4	28
60	Natural polyamines and synthetic analogs modify the growth and the morphology of Pyrus communis pollen tubes affecting ROS levels and causing cell death. *Plant Science*, **2015**, 239, 92-105	5.3	26
59	WB 4101-related compounds. 2. Role of the ethylene chain separating amine and phenoxy units on the affinity for alpha(1)-adrenoreceptor subtypes and 5-HT(1A) receptors. *Journal of Medicinal Chemistry*, **1999**, 42, 4214-24	8.3	26

58	Progress in acetylcholinesterase inhibitors for Alzheimer's disease: an update. *Expert Opinion on Therapeutic Patents*, **2008**, 18, 387-401	6.8	24
57	Hexahydrochromeno[4,3-b]pyrrole derivatives as acetylcholinesterase inhibitors. *Journal of Medicinal Chemistry*, **2001**, 44, 105-9	8.3	24
56	Design, synthesis, and biological activity of methoctramine-related tetraamines bearing an 11-acetyl-5,11-dihydro-6H-pyrido[2,3-b][1,4] benzodiazepin-6-one moiety: structural requirements for optimum occupancy of muscarinic receptor subtypes as revealed by symmetrical and unsymmetrical polyamines. *Journal of Medicinal Chemistry*, **1994**, 37, 3363-72	8.3	24
55	Targeting the Nrf2/Amyloid-Beta Liaison in Alzheimer's Disease: A Rational Approach. *ACS Chemical Neuroscience*, **2017**, 8, 1618-1627	5.7	23
54	Pharmacophore Hybridization To Discover Novel Topoisomerase II Poisons with Promising Antiproliferative Activity. *Journal of Medicinal Chemistry*, **2018**, 61, 1375-1379	8.3	23
53	In Vivo Characterization of ARN14140, a Memantine/Galantamine-Based Multi-Target Compound for Alzheimer's Disease. *Scientific Reports*, **2016**, 6, 33172	4.9	23
52	Merging memantine and ferulic acid to probe connections between NMDA receptors, oxidative stress and amyloid-peptide in Alzheimer's disease. *European Journal of Medicinal Chemistry*, **2019**, 180, 111-120	6.8	22
51	Synthesis of monomeric derivatives to probe memoquin's bivalent interactions. *Journal of Medicinal Chemistry*, **2011**, 54, 8299-304	8.3	22
50	The design of novel methoctramine-related tetraamines as muscarinic receptor subtype selective antagonists. *Life Sciences*, **1995**, 56, 837-44	6.8	21
49	Synthetic polyamines: an overview of their multiple biological activities. *Amino Acids*, **2010**, 38, 383-92	3.5	20
48	Search for alpha 1-adrenoceptor subtypes selective antagonists: design, synthesis and biological activity of cystazosin, an alpha 1D-adrenoceptor antagonist. *Bioorganic and Medicinal Chemistry Letters*, **1998**, 8, 1353-8	2.9	19
47	Polymethylene tetraamine backbone as template for the development of biologically active polyamines. *Medicinal Research Reviews*, **2003**, 23, 200-33	14.4	19
46	Analysis of the muscarinic receptor subtype mediating inhibition of the neurogenic contractions in rabbit isolated vas deferens by a series of polymethylene tetra-amines. *British Journal of Pharmacology*, **2001**, 132, 1009-16	8.6	19
45	Synthetic organic ligands active at voltage-gated calcium channels. *Annals of the New York Academy of Sciences*, **1991**, 635, 123-38	6.5	19
44	Nature-Inspired Multifunctional Ligands: Focusing on Amyloid-Based Molecular Mechanisms of Alzheimer's Disease. *ChemMedChem*, **2016**, 11, 1309-17	3.7	19
43	Exploring the effects of isothiocyanates on chemotherapeutic drugs. *Expert Opinion on Drug Metabolism and Toxicology*, **2014**, 10, 25-38	5.5	17
42	Search for selective antagonists at alpha 1-adrenoreceptors: neutral or negative antagonism?. *Il Farmaco*, **1998**, 53, 278-86		17
41	Heterocyclic inhibitors of AChE acylation and peripheral sites. *Il Farmaco*, **2005**, 60, 465-73		17

40	Novel xanthone-polyamine conjugates as catalytic inhibitors of human topoisomerase II. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 4687-4693	2.9	16
39	Multitarget drug design strategy in Alzheimer's disease: focus on cholinergic transmission and amyloid-β aggregation. *Future Medicinal Chemistry*, **2017**, 9, 953-963	4.1	16
38	Design, synthesis and biological evaluation of new naphtalene diimides bearing isothiocyanate functionality. *European Journal of Medicinal Chemistry*, **2012**, 48, 124-31	6.8	15
37	Isothiocyanate synthetic analogs: biological activities, structure-activity relationships and synthetic strategies. *Mini-Reviews in Medicinal Chemistry*, **2014**, 14, 963-77	3.2	15
36	Naphthalene diimide-polyamine hybrids as antiproliferative agents: Focus on the architecture of the polyamine chains. *European Journal of Medicinal Chemistry*, **2017**, 128, 107-122	6.8	14
35	Cytotoxicity of methoctramine and methoctramine-related polyamines. *Chemico-Biological Interactions*, **2009**, 181, 409-16	5	14
34	Progress in acetylcholinesterase inhibitors for Alzheimer's disease. *Expert Opinion on Therapeutic Patents*, **2006**, 16, 811-823	6.8	14
33	Methoctramine analogues inhibit responses to capsaicin and protons in rat dorsal root ganglion neurons. *European Journal of Pharmacology*, **2004**, 505, 37-50	5.3	14
32	Structure-activity relationships of methoctramine-related polyamines as muscular nicotinic receptor noncompetitive antagonists. 2. Role of polymethylene chain lengths separating amine functions and of substituents on the terminal nitrogen atoms. *Journal of Medicinal Chemistry*, **2002**, 45, 1860-78	8.3	14
31	Design, synthesis and biological activity of some tetraamines related to methoctramine and 4-DAMP. *Bioorganic and Medicinal Chemistry Letters*, **1995**, 5, 785-790	2.9	14
30	Distinct biological responses of metastatic castration resistant prostate cancer cells upon exposure to G-quadruplex interacting naphthalenediimide derivatives. *European Journal of Medicinal Chemistry*, **2019**, 177, 401-413	6.8	12
29	Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 1001-1004	2.9	12
28	Synthetic polyamines as potential amine oxidase inhibitors: a preliminary study. *Amino Acids*, **2012**, 42, 913-28	3.5	12
27	Novel polyamine analogues: from substrates towards potential inhibitors of monoamine oxidases. *European Journal of Medicinal Chemistry*, **2013**, 70, 88-101	6.8	12
26	LC determination of leuprolide component amino acids in injectable solution by phanquinone pre-column derivatization labelling procedure. *Journal of Pharmaceutical and Biomedical Analysis*, **2005**, 37, 1135-41	3.5	12
25	Analogues of prazosin that bear a benextramine-related polyamine backbone exhibit different antagonism toward alpha1-adrenoreceptor subtypes. *Journal of Medicinal Chemistry*, **2001**, 44, 362-71	8.3	12
24	Quinazoline based α-adrenoreceptor antagonists with potent antiproliferative activity in human prostate cancer cell lines. *European Journal of Medicinal Chemistry*, **2017**, 136, 259-269	6.8	11
23	Novel Polyamine-Naphthalene Diimide Conjugates Targeting Histone Deacetylases and DNA for Cancer Phenotype Reprogramming. *ACS Medicinal Chemistry Letters*, **2017**, 8, 1218-1223	4.3	11

22	Synthetic polyamines activating autophagy: effects on cancer cell death. *European Journal of Medicinal Chemistry*, **2013**, 67, 359-66	6.8	11
21	Combined inhibition of the EGFR/AKT pathways by a novel conjugate of quinazoline with isothiocyanate. *European Journal of Medicinal Chemistry*, **2016**, 117, 283-91	6.8	11
20	Polyamine Conjugation as a Promising Strategy To Target Amyloid Aggregation in the Framework of Alzheimer's Disease. *ACS Medicinal Chemistry Letters*, **2016**, 7, 1145-1150	4.3	11
19	Design, synthesis, and biological activity of methoctramine-related polyamines as putative G(i) protein activators. *Journal of Medicinal Chemistry*, **2001**, 44, 4035-8	8.3	9
18	Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase II and II *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 2961-2968	2.9	8
17	Antagonist binding profile of the split chimeric muscarinic m2-trunc/m3-tail receptor. *European Journal of Pharmacology*, **1998**, 355, 267-74	5.3	8
16	Structure-activity relationships of methoctramine-related polyamines as muscarinic antagonist: effect of replacing the inner polymethylene chain with cyclic moieties. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 2312-21	3.4	8
15	Memantine Derivatives as Multitarget Agents in Alzheimer's Disease. *Molecules*, **2020**, 25,	4.8	8
14	Lights and shadows of electrophile signaling: focus on the Nrf2-Keap1 pathway. *Future Medicinal Chemistry*, **2019**, 11, 707-721	4.1	7
13	Preparation, characterization and in vitro evaluation of sterically stabilized liposome containing a naphthalenediimide derivative as anticancer agent. *Drug Delivery*, **2015**, 22, 590-7	7	7
12	Study of the cytotoxic effects of the new synthetic Isothiocyanate CM9 and its fullerene derivative on human T-leukemia cells. *Toxins*, **2015**, 7, 535-52	4.9	6
11	Exploiting RNA as a new biomolecular target for synthetic polyamines. *Gene*, **2013**, 524, 232-40	3.8	5
10	In vitro and in vivo evaluation of polymethylene tetraamine derivatives as NMDA receptor channel blockers. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 3901-4	2.9	5
9	Design, synthesis, and biological evaluation of pirenzepine analogs bearing a 1,2-cyclohexanediamine and perhydroquinoxaline units in exchange for the piperazine ring as antimuscarinics. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 7311-20	3.4	5
8	Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II over *Journal of Medicinal Chemistry*, **2020**, 63, 12873-12886	8.3	4
7	Benextramine and derivatives as novel human monoamine oxidases inhibitors: an integrated approach. *FEBS Journal*, **2019**, 286, 4995-5015	5.7	3
6	Design, synthesis and biological activity of some 4-DAMP- related compounds. *Bioorganic and Medicinal Chemistry Letters*, **1995**, 5, 2325-2330	2.9	3
5	Exploring the activity of polyamine analogues on polyamine and spermine oxidase: methoctramine, a potent and selective inhibitor of polyamine oxidase. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2019**, 34, 740-752	5.6	2

4	Recent advances in the design and synthesis of prazosin derivatives. *Expert Opinion on Drug Discovery*, **2006**, 1, 395-407	6.2	2
3	[4-[[N-(3-chlorophenyl)carbamoyl]oxy]-2-butynyl]-trimethylammonium (McN-A-343)-related compounds. Effect of the butynyl chain inclusion into an aromatic unit on the potency for muscarinic receptors. *Bioorganic and Medicinal Chemistry*, **2000**, 8, 681-9	3.4	2
2	Polyamines May Modulate Both G Protein-Coupled Receptors and G Proteins. *Medicinal Chemistry Research*, **2004**, 13, 63-73	2.2	1
1	1-Adrenoreceptor antagonists bearing a quinazoline or a benzodioxane moiety. *Pharmacochemistry Library*, **2000**, 31, 181-190		